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We evaluated associations of tibial lead levels with polymorphisms in the vitamin D receptor
(VDR) in 504 formerorganolea manauri workerswithpastexposure to lead. Inthis cross-
sectional study, we measured tibia! lead by109Cd K-shellX-rayfluorescence. Tibial leadwas eval-
uated in subjects with different VDR genotypes defined using the BsmI restriction enzyme,
adjusting for confoundingvariables. Studyparticipants had a mean age ± SD of57.4 ± 7.6years.
A total of 169 (33.5%) subjects were homozygous for the Bsd restrction site (designated bb),
251 (49.8%) were heterozygous (Bb), and 84 (16.7%) were homozygous for the absence ofthe
restriction site (BR). Among all ofthe studysubjects, tibial lead concentrations were low, with a
mean ± SD of 14.4 ± 9.3 pgPb/g bone mineral. There were only small differences in tibial lead
concentrations by VDRgenotype, withmean ± SD tibia!lead concentrations of13.9 ± 7.9, 14.3 ±
9.5, and 15.5 ± 11.1 in subjectswith bb, Bb, and BA respectively. In a multiple linear regression
model oftibia!leadconcentrations, the VDRgenotypemodified the relation between age andtib-
ial lead concentrations; subjectswith the Ballele hadlarger increases in tibial lead concentrations
with increasing age (0.37, 0.48, and 0.67 pglg per year ofage in subjects with bb, Bb, and BA
respectively; the adjustedp-value for trend in slopes = 0.04). The V)Rgenotype also modified
the relation betweenyears sincelast exposure tolead and tibial lead concentrations. Subjects with
bbevidenced an average decline in tibial lead concentrations of0.10 pg/gperyear since their last
exposure to lead, whereas subjects with Bband BBevidenced average increases of0.03 and 0.11
pg/gperyear, respectively(theadjustedp-valuefortrendin slopes = 0.01). Polymorphisms in the
vitamin D receptormodifiedtherelationsofage andyears sincethe lastexposure to leadwith tib-
ial lead concentrations. Although controversy remains on the influence ofthe VD)Rgenotype on
bone mineral density, the data suggest that variant VDR alleles modify lead concentrations in
bone, either byinfluencing lead content or calcium content or both. Key workr. bone lead, vita-
min D receptor, X-ray fluorescence. Environ Health Perspect 108:199-203 (2000). [Online
20January2000]
httpn/e.mpnetl.niehs.nih.rov/doac/2000/l 08p09.9-203scwarstabstraetbhm
Interactions between lead and calcium have
long been recognized. For example, both cal-
cium deficiency and calcitriol (la,25-dihy-
droxyvitamin D) result in increased lead
absorption from the gastrointestinal tract
(1,4; blood lead levels are lower in children
with higher dietary calcium intakes (3);
dietarycalcium can reducebonelead accumu-
lation and its mobilization during pregnancy
and lactation in animals (4); low calcium
intake during pregnancy and lactation results
in greater mobilization ofmaternal skeletal
leadstores in humans (5,6); andlead accumu-
lates in bone, a calcium-rich tissue (7-9).
Lead also appears to affect parathyroid hor-
mone and calcitriol levels in serum, with
moderate lead levels increasing the levels of
parathyroid hormone and calcitriol (10), and
toxic levels decreasing the renal synthesis of
calcitriol (11).
In target tissues, calcitriol exerts its effects
after binding to the vitamin D receptor
(VDR). Several restriction fragment length
polymorphisms (RFLPs) have been identified
in the VDRgene (14. The RFLPs are in the
nontranslated region of the VDR gene, and
thus would not be expected to influence the
binding affinity ofthe receptor for its ligand,
calcitriol (13). However, one study did not
find a difference in duodenal mucosal recep-
tor density by VDR genotype, which was
thought to be another way the VDR poly-
morphisms could influence bone mineral
density (13). These RFLPs have been associ-
ated with differences in circulating osteocal-
cin levels (14 and in bone mineral density
(14-18). However, the association of VDR
polymorphisms and bone mineral density
remains controversial (19-24).
Most studies have focused on the BsmI
polymorphism; this restriction enzyme results
in three genotypes: bb, Bb, and BB. The
absence ofthe restriction site, termed BB, has
a prevalence in Caucasian populations
ranging from 7 to 32% (15). Study subjects,
mainly women, with the BB genotype have
up to 10-15% lower bone mineral densities
than subjects with the bb genotype (15). A
meta-analysis concluded that the average
effect size across all published studies, com-
paring bone mineral densities in subjects
with BBto those with bb, was 2.4% lower at
the hip, 2.5% lower at the spine, and 1.7%
lowerat thedistal radius (15).
To date, no studies have evaluated bone
lead concentrations by VDRgenotype. Bone
lead content can be measured by X-ray fluo-
rescence (XRF), thus providing an estimate
of lifetime exposure to lead (7-9). In the
XRF technique, bone lead concentration is
normalized to bone mineral content, provid-
ing an estimate in micrograms lead per gram
bone mineral. We report a study of tibial
lead concentrations by VDRgenotype in for-
mer organolead manufacturing workers
whose last occupational exposure to lead
occurred an average of 18 years before their
bone lead measurement.
Methods
Study design and overview. Data for the
studywere derived from a 4-year prospective
evaluation ofcentral and peripheral nervous
system function in current and former
employees of a chemical manufacturing
facility in the eastern United States that pro-
duced tetraethyl and tetramethyl lead
(25-2. All subjects had past exposure to
organic and inorganic lead and none were
currently exposed to lead. Subjects were
enrolled over a 3-year period and were fol-
lowed from 2 to 4 years. This work is a
cross-sectional analysis of tibial lead levels
obtained in the thirdyear ofthe study.
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Selection and recruitment ofstudy sub-
jects. The recruitment and selection ofstudy
subjects have been previously described by
Schwartz et al. (25-27). Of the 703 former
lead workers enrolled in the study, 84% of
the eligible subjects completed tibial lead
measurements. Of the 543 subjects who
completed tibial lead measurements, 93%
completed VDRgenotyping.
Data collection. The study was approved
by the Committee for Human Research at
the Johns Hopkins School of Hygiene and
Public Health (Baltimore, MD), and all sub-
jects provided informed written consent. Data
collection procedures have been described by
Schwartz et al. (25,26). In the first year ofthe
study, subjects provided a 10-mL blood speci-
men by venipuncture. The specimen was
stored at -70°C as plasma, buffy coat, red
blood cells, and whole blood. V/DRgenotyp-
ing and blood lead levels were measured from
this sample obtained in the first year of the
study. During the third year ofthe prospec-
tive study, tibial lead was measured by 109Cd
KXRF at the midtibial shaft (7-9).
Tibial lead measurements. Schwartz et
al. (25) described the details of tibial lead
measurement in the former lead workers.
Tibial lead was assessed (in micrograms lead
per gram bone mineral) via a 30-min mea-
surement at the left midtibial shaft using
109Cd in a back-scatter geometry to fluoresce
K-shell X-rays from lead. These X-rays were
then quantitated to estimate the concentra-
tion of lead in bone, after normalization to
the elastic scatter peak (due mainly to bone
mineral content), in micrograms lead per
gram bone mineral (7-9). 109Cd-based K-
shell XRF has been validated against atomic
absorption spectrometry of lead in bone
samples (7,28). For quality control and cali-
bration, bone lead phantoms constructed of
plaster-of-Paris with known concentrations
oflead ranging from 0 to 122 pg Pb/g plas-
ter were regularly measured by the XRF
system. Seven subjects had point tibial lead
Table 1. Characteristics of 504 former organolead
manufacturing workers who completed tibial lead
measurements and VDRgenotyping, 1996-1997.
Characteristic Mean ± SDa Range
Age(years) 57.4 ± 7.6 41-73
Exposure duration 8.3 ± 9.7 0-40
(years)
Duration since last 17.9±11.6 1-49
exposure (years)
Blood lead (pg/dL) 4.6 ± 2.6 1-20
Tibial lead (pg Pb/g 14.4 ± 9.3 -2-51b
bone mineral)
Race, Caucasian (%( 93
Current tobacco use (%) 20
Current alcohol use (%( 74
'Values shown are mean
± SD except where indicated.
bK-shell XRF can provide negative estimates of bone lead
concentration in subjects with low levels; all values were
used in the analysis (31).
concentration estimates that were < 0. All
point estimates were retained in the statisti-
cal analyses, including negative values,
because this method minimizes bias and
does not require censoring ofdata (29).
Vitamin D receptor genotyping.
Genomic DNA was extracted from whole
blood by using the QIAamp Blood Kit
(QIAGEN, Hilden, Germany). The BsmI
polymorphic site in intron 8 was amplified
by polymerase chain reaction (PCR) using
the primers originating in exon 7 (primer 1:
5'-CAACCAAGACTACAAGTAC-
CGCGTCAGTGA-3') and intron 8
(primer 2: 5'-AACCAGCGGGAAGAG-
GTCAAGGG-3'). The reaction was com-
pleted in a 50-pL reaction volume containing
0.3 ng DNA, 0.2 mM ofeach primer, 1.25
units Amplitaq DNA polymerase (Perkin-
Elmer, Branchburg, NJ), 1.25 mM dNTP,
10 mM Tris-HCL, pH 8.3 (at 25°C), 50
mM KCI, 1.5 mM MgCl2, and 0.001%
(weight/volume) gelatin. We used the fol-
lowing PCR cycle conditions: holding at
94°C for 5 min, then 35 cycles ofdenatura-
tion at 94C for 30 sec, annealing at 60C
for 30 sec, and extension at 72°C for 1 min.
The amplification produced 825 base pair
fragments. After PCR amplification, 10 mL
was digested with 5 units BsmI (New
England Biolabs, Beverly, MA) at 65°C, as
described by the supplier. The digested sam-
ples were electrophoresed in 3% MetaPhor
agarose gels (FMC Bioproducts, Rockland,
ME) in tris base EDTA buffer. Gels were
stained with ethidium bromide, visualized
on a transilluminator under ultraviolet light,
and photographed.
Statistical analysis. Our first goal ofthe
analysis was to determine whether there were
differences in mean tibial lead levels among
the three VDRgenotype groups. This initial
analysis revealed that age and the years since
the last exposure to lead were important con-
founding variables. Thus, our second major
goal was to determine if the VDR genotype
modified relations between age and the years
since the last exposure to lead and tibial lead
concentrations. SAS statistical software pro-
grams were used for the data analysis (SAS
Institute, Inc., Cary, North Carolina). Mean
tibial lead levels were compared in subjects
with the bb, Bb, and BB genotypes by one-
way analysis ofvariance. Next, we used mul-
tiple linear regression to control for potential
confounding variables. In modeling tibial
lead levels (in microgram lead per gram bone
mineral), we started with our previously
published model (25) that controlled for age,
height, tobacco use (current vs. never and
previous vs. never), lead exposure duration
(with both linear and quadratic terms to
account for nonlinear relation), diabetes (yes
vs. no), regular exercise that induced sweat-
ing (yes vs. no), and height. The VDRgeno-
type was then added to this model in one of
two ways: first, as a pair of indicator vari-
ables in which bb served as the reference
group, and second, as a trinaryvariable (0, 1,
2) corresponding to bb, Bb, and BB, to test
for trends. Effect modification ofthe VDR
genotype with age and years since the last
exposure to leadwas determined byexamining
the significance of cross-product terms of
VDR genotype indicators with age and years
since the last exposure, respectively. Nonlinear
relations forage oryears sincethelastexposure
were evaluated by inclusion of quadratic
terms, but because no significant curvilinear
relations were identified, onlythe linearresults
are presented. All regression relations were
evaluated for the assumptions implicit in
Table 2. Results of linear regression modeling of tibial lead levels, evaluating interactions between VDR
genotype and age (model 1) or years since the last exposure (YSLE) to lead (model 2) in 504 former
organolead manufacturing workers, 1996-1997.
Independentvariables Units ofP-coefficient ,B-Coefficient P SE p-Valuea
Model 1b
Age Bone mineral peryear(pg Pb/g) 0.368 0.087 <0.01
Years since last exposure Bone mineral peryear(pg Pb/g) 0.005 0.042 0.91
VDR-Bb Bone mineral (pg Pb/g) -5.542 6.013 0.36
VDR-BB Bone mineral (pg Pb/g) -15.910 8.277 0.06
Age x VDR-Bbf Bone mineral peryear(pg Pb/g) 0.107d 0.104 0.30
Agex VDR-B8 Bonemineralperyear(pgPb/g) 0.302d 0.143 0.04
Model 2b
Age Bone mineral peryear(pg Pb/g) 0.476 0.055 < 0.01
Years since last exposure Bone mineral peryear(pg Pb/g) -0.096 0.060 0.11
VDR-Bb Bone mineral (pg Pb/g) -1.544 1.440 0.28
VDR-BB Bone mineral (pg Pb/g) -2.240 1.912 0.24
YSLE x VDR-Bbc Bone mineral peryear(pg Pb/g) 0.122d 0.068 0.07
YSLE x VDR-Bb' Bone mineral peryear(pg Pb/g) 0.205d 0.088 0.02
'From 3/SE 13; p-values may not correspond exactly because of rounding, to three significant digits, oftheP-coefficients
and the SEs. blhese models also controlled for exposure duration (linear and quadratic terms), tobacco use (currentvs.
never and past vs. never), history of diabetes, height, and exercise that induced sweating, to be consistent with prior
research (25). Olnteraction terms evaluating whether influence of age (model 11 or YSLE to lead (model 2) differs by VDR
genotype. dp-Values fortrends in slopes with age (model 1) across VDRgroups = 0.04, and foryears since the last expo-
sure to lead (model 2) across VDRgroups =0.01.
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linear regression, including dependent vari-
able normality, linearity, lack of multicolin-
earity, and equality ofvariances. One subject
with the bb genotype who had an extreme
tibial lead value was removed from the analy-
sis because of the disproportionate influence
thisvalue hadon the regression modeling.
Results
The 504 subjects who completed tibial lead
measurements and VDR genotyping were
primarily Caucasian (93%). Their mean age
± SD was 57.4 ± 7.6 years, ranging from 41
to 73 years (Table 1). Tibial lead concentra-
tions and blood lead levels were low, ranging
from -2 to 51 pg/g and from 1 to 20 pg/dL,
respectively (Table 1). A total of 169
(33.5%) subjects were homozygous for the
BsmI restriction site (designated bb), 251
(49.8%) were heterozygous (Bb), and 84
(16.7%) were homozygous for the absence
ofthe restriction site (BB).
There were only small differences in
unadjusted tibial lead concentrations by VDR
genotype, with mean ± SD tibial lead levels of
13.9 ± 7.9, 14.3 ± 9.5, and 15.5 ± 11.1 in
subjects with bb, Bb, and BB, respectively.
Relationships between age, lead exposure
duration, height, tobacco use, diabetes, exer-
cise, and tibial lead levels have been described
by Schwartz et al. (25). After adjustment for
these factors, the trend of increasing tibial
lead levels across the bb, Bb, and BB groups
did not achieve statistical significance (adjust-
edp-value forlineartrend = 0.16).
Linear regression indicated that the VDR
genotype modified the relations between age
and tibial lead concentrations and years since
the last exposure to lead and tibial lead con-
centrations (Table 2). After adjusting for the
previously identified confounding variables
(25), on average, subjects with the B allele
had larger increases in tibial lead concentra-
tions with increasing age [0.37, 0.48, and
0.67 jig/g per year ofage in subjects with bb,
Bb, and BB, respectively; adjustedp-value for
trend in slopes = 0.04; model 1 (Table 2), and
Figure IA]. VDR also modified the relation-
ship between years since the last exposure to
lead and tibial lead concentrations. Subjects
with bb had, on average, a decline in tibial
lead concentration of0.10 1ig/g peryear since
their last exposure to lead, whereas subjects
with Bband BBhadslight increases [0.03 and
0.11 pg/g per year, respectively; adjusted p-
value for trend in slopes = 0.01; model 2
(Table 2) and Figure 1B]. The correlation
between age and years since the last exposure
to leadwas onlymoderate (Pearson's r= 0.33,
p < 0.01).
In former lead workers without ongoing
exposure to lead, bone lead stores are the
main contributor to current blood lead levels.
However, the VDRgenotype did not modify
the relation between blood lead levels
(dependent variable) and tibial lead concen-
trations (data notshown).
Discussion
Because calcitriol binds to the vitamin D
receptor, and because there is evidence that
the VDR genotype influences, for example,
bone mineral density and serum osteocalcin
levels, it is likely that the VDR genotype
influences the kinetics of calcium. Lead is a
cation that behaves like calcium in biologic
systems; therefore, we hypothesized that the
VDR genotype influences lead uptake and
retention in bone storage pools. In previous
studies, the BBgenotype was associated with
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bone mineral densities that were on average
2-10% lower than those in individuals with
bb (15). Few studies have evaluated the asso-
ciation between the VDRgenotype and bone
mineral density in men, but one recent study
reported that men under 50 years ofage with
BBhad forearm bone densities that were 7%
lower, on average, than densities in men with
bbor Bb, possibly because oflarger bone size
rather than reduced bone mass (30). Our
data reveal that the VDR genotype modifies
the apparent kinetics oflead in bone in men
with ages ranging from 40 to 70 years. The
associations of both age and years since the
last exposure to lead with tibial lead concen-
trations differed by genotype. The findings
Age(years)
0 10 20 30 40 W
Timesincethe lastexposure(years)
Figure 1. (A) Plot of the results of model 1, Table 2, for the relation of age and tibial lead levels by VDR
genotype, adjusting for confounding variables, in 504 former organolead workers. The solid line is for sub-
jects with bb, the dotted line is for subjects with Bb, and the dashed line is for subjects with 88. The
slopes ofthe lines are 0.368, 0.475, and 0.670 pg lead/g bone mineral per year of age, in subjects with bb,
Bb, and 88, respectively (p-value fortrend in slopes = 0.04). (8) Plot ofthe results of model 2, Table 2, for
the relation of years since the last exposure to lead and tibial lead levels by VDR genotype, adjusting for
confounding variables, in 504 former organolead workers. The solid line is forsubjects with bb, the dotted
line is for subjects with Bb, and the dashed line is for subjects with 88. The slopes ofthe lines are -0.096,
0.026, and 0.109 pg lead/g bone mineral per year since the last exposure to lead, in subjects with bb, Bb,
and 88, respectively (p-value fortrend in slopes =0.01).
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also exhibited trends with the number of
copies ofthe B allele. More copies ofB were
associated with larger increases in bone lead
concentrations with increasing age, and no
declines in concentrations with increasing
years since the last exposure to lead, relative
to subjects with the bbgenotype.
For our study subjects, peak tibial lead
concentrations should have been achieved at
the end ofthe occupational exposure to lead,
then remained stable or slowly dedined with
increasing duration since the last exposure to
lead, unless a significant environmental expo-
sure pathway was present. Numerous studies
have documented that in cross-sectional
analysis ofbone lead and age, bone lead con-
centrations increase with increasing age (31).
However, one recent longitudinal study
reported that tibial lead concentrations evi-
denced no changes when measured twice over
a 3-year period in 70 community exposed
menwith an average ageof66years (31), sug-
gesting that the apparent association with age
represents a birth cohort effect rather than a
true increase in tibial lead concentration over
time. Thus, a decrease in tibial lead concen-
tration with increasing years since the last
exposure to lead is the most likely scenario as
theleadslowlyclears from bone stores.
Tibial lead levels are normalized to bone
mineral content, so observed differences in
tibial lead concentrations could be due to
differences in bone lead content, bone min-
eral density, or both. Because bone mineral
is the denominator ofthe XRF technique, a
decrease in bone mineral densitywould yield
an apparent increase in tibial lead concentra-
tion. Peak mineral density ofcortical bone is
probably attained at 30-35 years of age.
After 40-50 years ofage, cortical bone min-
eral density declines by approximately 0.3 to
0.5% per year, but the tibia is not a high
mineral loss site (32). In our study subjects,
on average, tibial lead concentrations
increased by approximately 0.37 pg/g per
year ofage for subjects with bb, the increases
with age for subjects with Bb and BB were
29 and 105% higher per year, respectively.
These estimates are consistent with those of
previous studies, in which the VDR geno-
typewas not considered (33,34). These stud-
ies reported that tibial lead increased, on
average, 0.38 pg/g per year of age for sub-
jects from 20 to 55 years of age (33) and
0.63 pg/g peryear ofage in middle-aged and
elderly men with a mean age of 67 years
(34). Among study subjects, the mean tibial
lead level was 14 pg/g; therefore, increases in
tibial lead concentrations of0.37, 0.48, and
0.67 jig/g per year of age for subjects with
bb, Bb, and BB, respectively, represent
increases of 2.6, 3.4, and 4.8% per year of
age, respectively. These values seem tOO high
to be solely due to bone mineral loss. It is
thus likely that the VDR genotype not only
influences measured tibial lead concentra-
tions, possibly by affecting bone mineral
content, but also the actual accumulation
and/or retention oflead in bone.
With increasing years since the last expo-
sure to lead, on average, subjects with bbhad
declines in tibial lead concentrations of
approximately 0.10 pg/g per year since their
last exposure. In contrast and on average,
subjects with Bb and BB evidenced slight
increases in tibial lead concentrations with
increasing durations since their last exposure
to lead. The correlation between age and
years since the last exposure to lead was only
moderate; variability in age only accounted
for 11% of the variability in years since last
exposure (Pearson's r = 0.33, r2 = 0.109);
therefore, it is unlikely that the association of
years since the last exposure and tibial lead
concentration is merely due to thecorrelation
with age. The mean tibial lead concentration
in subjects with bbwas 14 pg/g, so an annual
decline of 0.10 pg/g is approximately 0.7%
per year. The increases in tibial lead concen-
trations with increasing duration since the
last exposure for subjects with Bb and BB
(0.2 and 0.8%, respectively) are close to the
average fractional loss of bone mineral con-
tent with age. This suggests that the associa-
tion of tibial lead concentration with years
since the last exposure to lead, modified by
the VDRgenotype, could be due to a greater
average loss ofbone mineral content with age
in subjectswith the B allele.
Subjects with BB had the highest unad-
justed (and adjusted) average current tibial
lead concentrations. They also exhibited the
largest increases in tibial lead concentrations
with age and duration since the last expo-
sure. These relatively higher tibial lead con-
centrations could be due to higher initial
accumulation, longer retention, or both. The
cross-sectional data do not allow deter-
mination of the likely mechanism for these
observations. Ifthe current results from this
cross-sectional study are representative ofthe
actual clearance in individuals with different
VDR genotypes, the higher current levels
and slower clearance imply that the BB
genotype promotes the retention of lead in
bone. However, because the VDR genotype
likely influences bone mineral density, with
the BBgenotype promoting the loss ofbone
mineral (which would produce an artifactual
increase in measured tibial concentration), it
is possible that at least a portion of the
apparent slower clearance of the BB geno-
type is due to the loss ofboth lead and bone
mineral, with disproportionately more rapid
loss ofbone mineral with time, as compared
to that ofthe bband Bbgenotypes.
Thus, the data suggest that the VDR
genotype modifies current tibial lead
concentrations, possibly by influencing both
the kinetics oflead in bone and bone miner-
al content. The results have implications for
epidemiologic studies that use bone lead
measurements to predict health effects: this
genetic cause ofinterindividual differences in
tibial lead concentrations may need to be
assessed and adjusted for so that health
effects modeling would be more accurate. If
the VDR genotype affects the accumulation
and release oflead from bone, it may also be
an important source of inter-individual sus-
ceptibility to the health effects oflead.
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